We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Potential Biomarkers Found for Early Alzheimer's Diagnosis

By LabMedica International staff writers
Posted on 05 Nov 2013
The presymptomatic stage of Alzheimer’s disease (AD) occurs at least one decade before the clinical onset, highlighting the need for validated biomarkers that reflect this early period.

The success of future intervention strategies for AD will likely rely on the development of treatments, once a definitive diagnosis has been made early in the course of the disease, before irreversible brain damage occurs.

Scientists at Linköping University (Sweden) working with international collaborators, performed a targeted search for lysosomal network proteins in human cerebrospinal fluid (CSF). More...
They studied samples of spinal marrow from 20 Alzheimer's patients and an equal number of healthy control subjects. The screening was aimed at 35 proteins that are associated with the lysosomal network.

CSF levels of the core AD biomarkers, including Aβ1–42, T-tau and P-tau181P phosphorylated at threonine181, were determined using INNOTEST enzyme linked immunosorbent assay (ELISA) kits (Innogenetics; Ghent, Belgium). Albumin levels were measured by immunonephelometry on a Beckman Image Immunochemistry system (Beckman Instruments, Beckman Coulter; Brea, CA, USA). Western blots were performed on CSF samples and immunodetection of the bound antibodies was performed using Amersham ECL detection systems (GE Healthcare; Pittsburgh, PA, USA).

Of thirty-four candidate lysosomal network proteins, they found that only six proteins were increased, indicating that a specific subset of lysosomal network proteins is overexpressed in the CSF of AD patients. The scientists identified the six as the endosomal proteins rat sarcoma (ras) in the brain 3, (Rab3) andRab7; the early endosomal antigen 1 (EEA1); the lysosomal-associated membrane proteins 1 and 2 (LAMP-1, LAMP-2), and the autophagy microtubule-associated protein 1 light chain 3 (LC3) and all were significantly upregulated in the CSF of AD patients.

Katarina Kågedal, PhD, the lead author of the study said, “In victims of Alzheimer's, something happens to the lysosomes so that they can't manage to take care of the surplus of beta amyloid. They fill up with junk that normally is broken down into its component parts and recycled.” Her hope is that the group's discovery will contribute to early diagnoses of the illness, which is necessary in the first stage in order to be able to begin reliable clinical tests of candidates for drugs, but perhaps the six lysosomal proteins could also be targets for developing drugs. The study was published on October 8, 2013, in the journal Neuromolecular Medicine.

Related Links:

Linköping University
Innogenetics
Beckman Instruments 
 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.